AstraZeneca

The article details how a potential $400bn tie-up and merger between AstraZeneca and its US rival, Bristol Myers, ultimately unravelled. Had this mega-deal proceeded, it would have represented a notable return to major pharma megadeals.

A Medicare pilot program called GUARD, aimed at lowering drug prices through 'most-favored nation' pricing, could lose significant savings if rare disease drugs are excluded, according to biotech lobbying efforts. Additionally, reports of potential mergers between AstraZeneca and Bristol Myers Squibb have been denied by anonymous sources.

A senior source denied that AstraZeneca and Bristol Myers Squibb were ever in merger talks. A source close to the matter told Reuters there is 'no deal' and 'never was a deal to be done' between the two drugmakers.

AstraZeneca's potential merger with Bristol Myers Squibb could shift more of its revenue away from the UK and Europe, possibly leading to a New York relisting. US regulatory demands might require commitments to US research, manufacturing, and employment, further distancing the company from the UK. Recent trends show UK-based firms increasingly relisting in New York or being acquired by US rivals.

AstraZeneca and Bristol Myers Squibb are in talks that could result in a $400bn merger, creating the world’s fourth-largest drugmaker by market value.

The article covers a growing cyclosporiasis outbreak in Michigan leading to food stock declines, bipartisan support for Blanche for Attorney General, advancing Iran-Oman Hormuz talks following Trump's attack halt, easing oil prices and market rallies, AWS's fastest growth in five years, AstraZeneca's potential mega-merger with Bristol-Myers, Visa's acquisition of BioCatch, U.S.-Japan yen defense measures, U.S. manufacturing hitting a four-year high, and Apollo's selection of Austin for its second headquarters.

AstraZeneca Plc investors expressed disapproval of a proposed $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Sam Fazeli discussed the reaction to the deal.

AstraZeneca and Bristol-Myers Squibb suggest that larger financial resources enable greater investment in potential blockbuster drugs. The article highlights the advantage of enlarged balance sheets in pharmaceutical development.

AstraZeneca investors are expressing concerns about a potential $400 billion merger with Bristol Myers Squibb, citing risks related to an impending patent cliff and antitrust challenges.

AstraZeneca's stock fell amid merger talks with Bristol Myers Squibb, which could create a $400 billion drugmaker, while Amgen disclosed a cybersecurity incident involving stolen patient data. Investors questioned the strategic need for the proposed merger, and Bristol Myers Squibb's shares rose in premarket trading.

AstraZeneca stock declined following reports of merger discussions with Bristol Myers Squibb. The potential merger could create a company valued at nearly $400 billion, according to the Financial Times.

AstraZeneca shares were declining while Bristol-Myers Squibb shares rose amid reported deal talks between the two pharmaceutical companies. Analysts are uncertain about the potential motivations for a partnership between the firms.

Trump pushes for new Iran negotiations, the DOJ ends a controversial anti-weaponization fund, and the Senate unveils a short-term funding bill. Chip stocks are in focus after a July selloff, while the U.S. and Japan intervene to support yen markets. AstraZeneca explores a merger with Bristol-Myers.

AstraZeneca is holding discussions with Bristol Myers Squibb regarding a potential £300 billion merger. The talks could result in a major business consolidation between the two companies.

AstraZeneca shares fell 7% following a Financial Times report indicating the company has discussed a potential merger with Bristol Myers Squibb over several months.

AstraZeneca is in talks to acquire Bristol Myers Squibb in a potential $400bn merger, creating the world’s fourth-largest drugmaker. The deal would combine AstraZeneca's nearly £196bn market value with BMS's $133bn valuation.

AstraZeneca is in talks to acquire Bristol Myers Squibb in a potential $400bn merger, creating the world’s fourth-largest drugmaker. AstraZeneca, the UK’s second-biggest listed company, has a market value of nearly £196bn, while BMS, based in Princeton, is valued at $133bn.

AstraZeneca has explored an acquisition of Bristol Myers Squibb, though it is unclear if discussions are ongoing or will result in a transaction. AstraZeneca declined to comment, and Bristol Myers Squibb could not be reached for comment.

AstraZeneca and Bristol Myers Squibb are discussing a potential $400 billion merger. The article also references a migrant crossing in Ceuta and UEFA's response to a failed FIFA plan.

AstraZeneca is in talks with Bristol Myers Squibb to finalize a $400 billion megadeal, which would create one of the world's largest pharmaceutical groups with a combined value of nearly $400 billion.

AstraZeneca Plc explored an acquisition of Bristol Myers Squibb Co., which could create one of the world's largest drugmakers. Bristol Myers Squibb, with a $133 billion market capitalization, faces patent losses for key drugs like Eliquis and Opdivo, while AstraZeneca has a market value of about £196 billion. Bristol recently reported record quarterly sales of $13 billion driven by newer treatments.

AstraZeneca Plc has explored an acquisition of Bristol Myers Squibb Co., in a megadeal that would create one of the world’s largest drugmakers.

U.K. pharmaceutical company AstraZeneca is in talks with U.S. rival Bristol Myers Squibb for a potential $400 billion merger, as reported by the Financial Times.

Andhra Pradesh has partnered with AstraZeneca to establish a Genomic Solutions Centre in Amaravati, utilizing next-generation sequencing, AI, and genomic technologies for early cancer detection and personalized treatment. The project includes installing AI-enabled X-ray systems in government hospitals to improve diagnostic accuracy.

Chinese pharmaceutical companies are advancing in early-stage research and clinical trials but remain about a decade behind global leaders like AstraZeneca. AstraZeneca's CFO, Aradhana Sarin, noted that Chinese firms lack the capability for global clinical trials but may challenge Western competitors within 10 years. The rise of GLP-1 drugs for weight loss could reshape pharmaceutical strategies and cancer prevalence patterns.

AstraZeneca CEO Pascal Soriot warns that the US and European pharmaceutical industries risk falling behind China's rising pharmaceutical sector due to slower innovation. He urges Western drugmakers to adopt a faster pace, citing the automotive industry as an example of past stagnation.

AstraZeneca's core earnings per share increased to $2.63 in Q2, exceeding analyst expectations of $2.48. The company attributed the growth to strong cancer drug sales and maintained its full-year and 2030 outlooks.

Oil prices fell as the US and Iran paused hostilities, leading to declines in energy sector stocks like BP and Shell. AstraZeneca exceeded profit forecasts due to successful cancer treatments, while JD Sports and Vodafone saw share price increases.

European stocks rose as oil prices fell following a pause in US-Iran strikes, and AstraZeneca exceeded profit forecasts due to cancer treatments. The Stoxx Europe 600, FTSE 100, Cac 40, and Dax indices all saw gains, while UK government spending challenges remain unresolved.

A Tenth Circuit panel ruled that AstraZeneca is immune from a lawsuit filed by Brianne Dressen, who claimed injuries from a 2020 Covid-19 vaccine trial. The court held that the PREP Act shields the company from liability, including breach-of-contract claims, though it remanded the case to assess if AstraZeneca waived immunity in the informed consent form.

AI is accelerating biologic drug development by narrowing molecular candidates and enabling faster timelines, with companies like AstraZeneca using AI to tackle previously untreatable diseases. Puja Sapra of AstraZeneca highlights AI's role in optimizing drug design and increasing R&D productivity.

Arkansas Attorney General Tim Griffin sued pharmaceutical companies including Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, alleging they conspired to block healthcare providers from accessing discounted drugs under the 340B federal program. The companies are accused of imposing restrictive requirements to limit the use of contract pharmacies, which covered entities rely on to serve underserved communities.

President Donald Trump announced a plan to impose 100% tariffs on generic drugs starting August 2028, increasing to 200% in 2029, aiming to reshape pharmaceutical production in the U.S. The administration has not yet issued a formal order, while brand-name drug tariffs remain unchanged. Exemptions and lower rates apply to companies building U.S. plants and certain trade partners.

UK Prime Minister Andy Burnham aims to strengthen British business, but companies are shifting operations to the US and Asia due to the UK's weak economic growth and capital markets. Major firms like Reckitt Benckiser, AstraZeneca, and GSK derive significant revenue from overseas markets, while the UK lags in startup valuations compared to the US. The government and London Stock Exchange are offering incentives to retain businesses, but challenges persist.

The FDA approved Merck's Lipfendra, a cholesterol-lowering pill that outperforms traditional statins and offers an easier alternative to injectable treatments. The approval could improve heart disease prevention, with AstraZeneca developing a competing pill.

AstraZeneca's recent trial failure has raised concerns about the vulnerability of its pipeline premium. The company has been valued highly among European pharma firms based on consistent results.

Virginia rose to third place in CNBC’s annual ‘Top States for Business’ rankings, attributed to improvements in cost of living, housing, healthcare, and infrastructure. Governor Abigail Spanberger highlighted new laws and investments, including a $50 million boost to the Virginia Business Ready Sites Program and initiatives like InternshipsVA.

AstraZeneca's stock fell sharply after its late-stage heart drug trial for Wainua failed to reduce cardiovascular deaths and recurring heart events, causing a $27 billion drop in market value.

AstraZeneca and Ionis Pharmaceuticals reported that their heart disease drug, Wainua, failed in a pivotal trial for ATTR-CM, showing no improvement over placebo in reducing cardiovascular death and clinical events. The failure caused AstraZeneca's U.S. shares to drop 8% and London-listed shares to fall 9%, while Ionis shares fell 12%.

AstraZeneca's stock fell 9% following a heart drug trial that failed to meet its target. The decline reflects investor disappointment over the unmet clinical trial objective.